Resveratrol-associated renal toxicity

Toxicological Sciences

Volumn 82, Issue 2, 2004, Pages 614-619

  Crowell, James A ^a,e   Korytko, Peter J ^b   Morrissey, Robert L ^c   Booth, Tristan D ^d   Levine, Barry S ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Charles River Company   (United States)

^d INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^e Chemopreventive Agent Dev Res Grp   (United States)

Author keywords

Cancer chemoprevention; Kidney; Resveratrol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; CREATININE; HEMOGLOBIN; NITROGEN; RESVERATROL; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER DISEASE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL CHEMISTRY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; EPITHELIUM HYPERPLASIA; ERYTHROCYTE COUNT; FEEDING; FEMALE; FOOD INTAKE; HEMATOCRIT; HISTOPATHOLOGY; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY MASS; LEUKOCYTE COUNT; LIVER WEIGHT; MALE; NEPHROTOXICITY; NONHUMAN; RAT; UREA NITROGEN BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; ANTICARCINOGENIC AGENTS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INTUBATION, GASTROINTESTINAL; KIDNEY; KIDNEY DISEASES; LEUKOCYTE COUNT; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; ORGAN SIZE; RATS; SEX CHARACTERISTICS; STILBENES;

MORUS (PLANT); VITACEAE;

EID: 10044243554     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/kfh263     Document Type: Article

References (28)

1. Adhami, V. M., Afaq, F., and Ahmad, N. (2001). Involvement of retinoblastoma (pRB)-E2F/DP pathway during anti-proliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochem. Biophys. Res. Com. 288, 579-585.
2. Andlauer, W., Kolb, J., Siebert, K., and Furst, P. (2000). Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp. Clin. Res. 26, 47-55.
3. Banerjee, S., Bueso-Ramos, C., and Aggarwal, B. B. (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 62, 4945-4954.
4. Bertelli, A. A., Giovannini, L., Stradi, R., Urien, S., Tillement, J. P., and Bertelli, A. (1998). Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp. Clin. Res. 24, 51-55.
5. Bhat, K. P. L., Kosmeder, J. W., and Pezzuto, J. M. (2001a). Biological effects of resveratrol. Antioxid. Redox. Signal. 3, 1041-1064.
6. Bhat, K. P. L., Lantvit, D., Christov, K., Mehta, R. G., Moon, R. C., and Pezzuto, J. M. (2001b). Estrogenic and anti-estrogenic properties of resveratrol in mammary tumor models. Cancer Res. 61, 7456-7463.
7. de Santi, C., Pietrabissa, A., Spisni, R., Mosca, F., and Pacifici, G. M. (2000). Sulfation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica 30, 609-617.
8. Docherty, J. J., Smith, J. S., Fu, M. M., Stoner, T., and Booth, T. (2003). Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice. Antivir. Res. 61, 19-26.
9. Fremont, L. (2000). Biological effects of resveratrol. Life Sci. 66, 663-673.
10. Gehm, B. D., McAndrews, J. M., Chien, P. Y., and Jameson, J. L. (1997). Resveratrol, a polyphenolic compound found in grapes and wine, is an angonist for the estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 94, 14138-14143.
11. Gusman, J., Malonne, H., and Atassi, G. A. (2001). Reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22, 1111-1117.
12. Gustafsson, J.-A. (2003). What pharmacologists can learn from recent advances in estrogen signaling. Trends Pharmacol. Sci. 24, 479-485.
13. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., Fong, H. H., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220.
14. Joe, A. K., Liu, H., Suzui, M., Vural, M. E., Xiao, D. H., and Weinstein, I. B. (2002). Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin. Cancer Res. 8, 893-903.
15. Juan, M. E., Vinardell, M. P., and Planas, J. M. (2002). The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr. 132, 257-260.
16. Kuhnle, G., Spencer, J. P., Chowrimootoo, G., Schroeter, H., Debnam, E. S., Srai, S. K., Rice-Evans, C., and Hahn, U. (2000). Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem. Biophys. Res. Commun. 272, 212-217.
17. Manna, S. K., Mukhopadhyay, A., and Aggaarwal, B. B. (2000). Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappaB, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164, 6509-6519.
18. Martinez, J., and Moreno, J. J. (2000). Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 59, 865-870.
19. National Research Council (1996). Guide for the care and use of laboratory animals, National Academy Press, Washington, D.C.
20. Nonomura, S., Kanagawa, H., and Makimoto, A. (1963). Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-jo-kon (Polygonum Cuspidatum SIEB et ZUCC). Yukugaku Zasshi 83, 983-988.
21. 2 cell cycle arrest. Cancer Res. 64, 423-428.
22. Ramsey, T. L., Risinger, K. E., Jernigan, S. C., Mattingly, K. A., and Klinge, C. M. (2004). Extrogren receptor β isoforms exhibit differences in ligand-activated transcriptional activity in an estrogen response element sequence-dependent manner. Endocrinology 145, 149-160.
23. Savouret, J. F., and Quesne, M. (2002). Resveratrol and cancer: A review. Biomed. Pharmacother. 56, 84-87.
24. Schneider, Y., Duranton, B., Gosse, F., Schleiffer, R., Seiler, N., and Raul, F. (2001). Resveratrol inhibits intestinal tumorigenesis and modulates host defense related gene expression in an animal model of human familial adenomatous polyposis. Nutr. Cancer 39, 102-107.
25. She, Q. B., Huang, C. S., Zhang, Y. G., and Dong, Z. G. (2002). Involvement of c-jun NH2-terminal kinases in resveratrol-induced activation of P53 and apoptosis. Mol. Carcinog. 33, 244-250.
26. Surh, Y. J., Chun, K. S., Cha, H. H., Han, S. S., Keum, Y. S., Park, K. K., and Lee, S. S. (2001). Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res. 480, 243-268.
27. Turner, R. T., Evans, G. L., Zhang, M., Maran, A., and Sibonga, J. D. (1999). Is resveratrol an estrogen agonist in growing rats? Endocrinology 140, 50-54.
28. Yu, C., Shin, Y. G., Chow, A., Li, Y., Kosmeder, J. W., Lee, Y. S., Hirschelman, W. H., Pezzuto, J. M., Mehta, R. G., and van Breemen, R. B. (2002). Human, rat, and mouse metabolism of resveratrol. Pharm. Res. 19, 1907-1914.